Objective: Prediction of the mechanism of psyllium in improving renal fibrosis based on network pharmacology and molecular docking technology. Methods: The active ingredients of psyllium were queried and screened through the TCM Systematic Pharmacological Analysis Platform (TCMSP), and the targets of its active ingredients were predicted according to Pubchem and Swiss Target Prediction. Renal fibrosis-related targets were queried in GeneCards and OMIM, and the intersecting targets were mapped with the active ingredient targets. The protein-protein interaction (PPI) network of the intersecting targets was constructed by STRING and Cytoscape 3.7.2, and the GO and KEGG pathways enrichment analysis and visualization were performed by DAVID and microbiosis, and the psyllium-component-target-disease network diagram was constructed by Cytoscape 3.7.2 to predict its anti-renal fibrosis mechanism. Finally, the molecular docking technology verified the docking of the active ingredient and the protein, and further explored the mechanism of psyllium to improve renal fibrosis. Results: 455 targets of 9 active ingredients were obtained from psyllium, and 256 intersecting targets were obtained by intersecting with disease targets. GO and KEGG pathway enrichment analysis showed that psyllium mainly improved renal fibrosis through biological processes such as cancer pathway, PI3K-Akt and Rap1 signaling pathway, cell proliferation, inflammatory response and cell migration. Molecular docking analysis showed that the active ingredient was stably bound to the core target. Conclusion: In this study, it was found that psyllium mainly acts on core targets such as VEGFA, TNF, ALB, AKT1, IL-6 and EGFR, and plays an anti-renal role in reducing inflammatory responses, inhibiting cell proliferation and migration through cancer pathways, PI3K-Akt and Rap1 signaling pathways.
XU Nanbing
,
WU Guodong
,
ZHAO Longshan
,
BO Yukun
,
YANG Dan
,
GUO Jingjing
,
ZHU Junxuan
,
AN Ming
. The potential mechanism of Cheqianzi in improving renal fibrosis based on network pharmacology and molecular docking technology[J]. Journal of Baotou Medical College, 2026
, 42(1)
: 28
-34
.
DOI: 10.16833/j.cnki.jbmc.2026.01.006
[1] Chen F, Lu ZW, Dai EL. Research progress of Chinese and western medicine pathogenesis of renal fibrosis[J]. Liaoning J Tradit Chin Med, 2016, 2(6): 1243-1246.
[2] Yan H, Xu J, Xu Z, et al. Defining therapeutic targets for renal fibrosis: exploiting the biology of pathogenesis[J]. Biomed Pharmacother, 2021, 143: 112115.
[3] Fu R, Tajima S, Shigematsu T, et al. Establishment of an experimental rat model of tacrolimus-induced kidney injury accompanied by interstitial fibrosis[J]. Toxicol Lett, 2021, 341:43-50.
[4] 国家药典委员会. 中华人民共和国药典一部: 2020年版[M]. 北京: 中国医药科技出版社, 2020: 68-69.
[5] 徐硕, 徐文峰, 梁晓丽, 等. 车前子的化学成分及生物活性研究进展[J]. 西北药学杂志, 2019, 34(4): 567-568.
[6] 赵宏, 柴桂芳, 刘颖斐, 等. 车前子水煎液对痛风性肾病大鼠的肾保护作用及机制[J]. 中国实验方剂学杂志, 2018, 24(20): 108-114.
[7] Liu J, Liu J, Tong X, et al. Network pharmacology prediction and molecular docking-based strategy to discover the potential pharmacological mechanism of huai hua san against ulcerative colitis[J]. Drug Des Devel Ther, 2021, 15: 3255-3276.
[8] Zheng L, Jiang H, Li R, et al. The pharmacological mechanisms of xiaochaihutang in treating breast cancer based on network pharmacology[J]. Contrast Media Mol Imaging, 2022: 3900636.
[9] 孙绍庆, 王霞, 尚猛, 等. 基于网络药理学的车前子治疗高脂血症作用机制研究[J]. 广东化工, 2021, 48(12): 73-74, 97.
[10] 黄艺飞, 尹延哲, 邵忠林, 等. 基于网络药理学和分子对接探讨土茯苓-车前子干预尿酸性肾病作用机制[J]. 中国中医药图书情报杂志, 2023, 47(1): 21-26.
[11] Tan RZ, Wang C, Deng C, et al. Quercetin protects against cisplatin-induced acute kidney injury by inhibiting Mincle/Syk/NF-κB signaling maintained macrophage inflammation[J]. Phytother Res, 2020, 34(1): 139-152.
[12] Tu H, Ma D, Luo Y, et al. Quercetin alleviates chronic renal failure by targeting the PI3k/Akt pathway[J]. Bioengineered, 2021, 12(1): 6538-6558.
[13] Yin D, Cao JY, Yang Y, et al. Quercetin alleviates tubulointerstitial inflammation by inhibiting exosomes-mediated crosstalk between tubular epithelial cells and macrophages[J]. Inflamm Res, 2023, 72(5): 1051-1067.
[14] Kut K, Bartosz G, Soszyński M, et al. Antioxidant properties of hispidulin[J]. Nat Prod Res, 2022, 36(24): 6401-6404.
[15] Koc K, Geyikoglu F, Cakmak O, et al. The targets of β-sitosterol as a novel therapeutic against cardio-renal complications in acute renal ischemia/reperfusion damage[J]. Naunyn Schmiedebergs Arch Pharmacol. Mar, 2021, 394(3): 469-479.
[16] Ding J, Wang Y, Wang Z, et al. Luteolin ameliorates methamphetamine-induced podocyte pathology by inhibiting tau phosphorylation in mice[J]. Evid Based Complement Alternat Med, 2022, 5909926.
[17] Nelson AT, Camelio AM, Claussen KR, et al. Synthesis of oxygenated oleanolic and ursolic acid derivatives with anti-inflammatory properties[J]. Bioorg Med Chem Lett, 2015, 25(19): 4342-4346.
[18] Zhao D, Luan Z. Oleanolic acid attenuates renal fibrosis through TGF-β/Smad pathway in a rat model of unilateral ureteral obstruction[J]. Evid Based Complement Alternat Med, 2020, 2085303.
[19] Lungu CN, Mehedinti MC. Molecular motifs in vascular morphogenesis: vascular endothelial growth factor A (VEGFA) as the leading promoter of angiogenesis[J]. Int J Mol Sci, 2023, 24(15): 12169.
[20] Su CT, Jao TM, Urban Z, et al. LTBP4 affects renal fibrosis by influencing angiogenesis and altering mitochondrial structure[J]. Cell Death Dis, 2021, 12(10): 943.
[21] Chen J, Li D. Telbivudine attenuates UUO-induced renal fibrosis via TGF-β/Smad and NF-κB signaling[J]. Int Immunopharmacol, 2018, 55: 1-8.
[22] Kim IY, Park YK, Song SH, et al. Role of Akt1 in renal fibrosis and tubular dedifferentiation during the progression of acute kidney injury to chronic kidney disease[J]. Korean J Intern Med, 2021, 36(4): 962-974.
[23] Guo X, Zhu Y, Sun Y, et al. IL-6 accelerates renal fibrosis after acute kidney injury via DNMT1-dependent FOXO3a methylation and activation of Wnt/β-catenin pathway[J]. Int Immunopharmacol, 2022, 109: 108746.
[24] Chen X, Yu C, Hou X, et al. Histone deacetylase 6 inhibition mitigates renal fibrosis by suppressing TGF-β and EGFR signaling pathways in obstructive nephropathy[J]. Am J Physiol Renal Physiol, 2020, 319(6): F1003-F1014.
[25] Li D, Yu K, Feng F, et al. Hydroxychloroquine alleviates renal interstitial fibrosis by inhibiting the PI3K/Akt signaling pathway[J]. Biochem Biophys Res Commun, 2022, 610: 154-161.
[26] Liang Y, Sun X, Wang M, et al. PP2Acα promotes macrophage accumulation and activation to exacerbate tubular cell death and kidney fibrosis through activating Rap1 and TNFα production[J]. Cell Death Differ, 2021, 28(9): 2728-2744.
[27] Deng B, Yang W, Wang D, et al. Peptide DR8 suppresses epithelial-to-mesenchymal transition via the TGF-β/MAPK signaling pathway in renal fibrosis[J]. Life Sci, 2020, 261: 118465.
